Elixirgen Therapeutics Granted FDA Orphan Drug Designation for EXG-34217 for Treatment of ...
The FDA recently granted EXG-34217 Rare Pediatric Disease Designation (RPDD) and Regenerative Medicine Advanced Therapy (RMAT) Designation.
Billings Gazette2 天
Dr. Autumn Dugas, owner of RegenND, provides patients with nonsurgical platelet-rich plasma ...
Content by RegenND Naturopathic Clinic. From tennis elbow and Achilles tendonitis to osteoarthritis and rotator cuff injuries ...
PharmiWeb3 天
Global Gene Editing Tool Market Poised for Explosive Growth, Projected to Reach USD 3,713.1 ...
Gene Editing Tool Market AnalysisThe global gene editing tool market is on the cusp of a revolutionary expansion, projected to grow at an impressive CAGR of 18.4% from 2024 to 2034. Valued at USD 688.
Bionic Sight’s BS01 Gene Therapy Receives RMAT Designation from the FDA
Company shares preliminary results from Phase 1/2 clinical trial for patients with advanced Retinitis Pigmentosa (RP) NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Bionic Sight, Inc., a company ...